Recursion Granted Fast Track Designation For REC-4881 For Potential Treatment Of Familial Adenomatous Polyposis
SALT LAKE CITY, April 11, 2022 /PRNewswire/ -- Recursion (NASDAQ:RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the U.S. Food
Recursion Pharmaceuticals Q4 EPS $(0.38) Up From $(1.17) YoY, Sales $2.50M Down From $2.70M YoY
Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.38) per share. This is a 67.52 percent increase over losses of $(1.17) per share from the same period last year. The company reported $2.50
68 Biggest Movers From Friday
Gainers
Indonesia Energy Corporation Limited (NASDAQ: INDO) shares jumped 101.8% to close at $40.77 on Friday after jumping 39% on Thursday.
43 Stocks Moving In Friday’s Mid-Day Session
Gainers
VEON Ltd. (NASDAQ: VEON) rose 45.6% to $0.3830 after dropping 41% on Thursday.
SVB Leerink Downgrades Recursion Pharmaceuticals to Market Perform, Lowers Price Target to $10
SVB Leerink analyst Mani Foroohar downgrades Recursion Pharmaceuticals (NASDAQ:RXRX) from Outperform to Market Perform and lowers the price target from $32 to $10.
SVB Leerink Maintains Outperform on Recursion Pharmaceuticals, Raises Price Target to $32
SVB Leerink analyst Mani Foroohar maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Outperform and raises the price target from $30 to $32.